PD-1/PD-L1
- Inhibitory Selectivity
- Solubility
| Catalog No. | Product Name | Solubility(25°C) | ||
|---|---|---|---|---|
| Water | DMSO | Alcohol | ||
| S8158 | PD-1/PD-L1 Inhibitor 3 | 100 mg/mL | -1 mg/mL | -1 mg/mL |
| S7912 | BMS202 (PD-1/PD-L1 inhibitor 2) | <1 mg/mL | 83 mg/mL | 83 mg/mL |
| S8549 | AUNP-12 | 100 mg/mL | -1 mg/mL | -1 mg/mL |
| S7911 | PD-1/PD-L1 inhibitor 1 | 95 mg/mL | 95 mg/mL | 95 mg/mL |
- PD-1/PD-L1 Inhibitors (7)
- PD-1/PD-L1 Antibodies (3)
- New PD-1/PD-L1 Products
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| A2002 |
NivolumabNivolumab is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD. |
||
| A2004 |
AtezolizumabAtezolizumab is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD. |
||
| A2005 |
PembrolizumabPembrolizumab is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD. |
||
| S8158 |
PD-1/PD-L1 Inhibitor 3PD-1/PD-L1 Inhibitor 3（Programmed Death-1/Programmed Death-Ligand 1 Inhibitor 3）is a Macrocyclic inhibitor of PD-1/PD-L1 interaction with IC50 of 5.6 nM |
||
| S7912 |
BMS202 (PD-1/PD-L1 inhibitor 2)BMS202 (PD-1/PD-L1 inhibitor 2) is a small-molecule PD-1/PD-L1 interaction inhibitor with IC50 of 18 nM. |
||
| S8549 |
AUNP-12AUNP-12, a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway. |
||
| S7911 |
PD-1/PD-L1 inhibitor 1PD-1/PD-L1 inhibitor 1 is a small-molecule inhibitor of PD-1/PD-L1 interaction with IC50 of 6 nM. |
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| A2013New |
DurvalumabDurvalumab is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa. |
||
| A2016New |
CamrelizumabCamrelizumab is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1 with immune checkpoint inhibitory and antineoplastic activities. |
||
| A2017New |
SpartalizumabSpartalizumab is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. It binds to PD-1 with high affinity and inhibits the biological activity of PD-1. |
